Wells Fargo Cuts PT on Globus Medical (GMED) Despite Q1 Sales and EPS Beat

Globus Medical, Inc. (NYSE:GMED) is one of the best robotic surgery stocks to buy. Wells Fargo cut the price target on Globus Medical, Inc. (NYSE:GMED) to $103 from $104 on May 8, maintaining an Overweight rating on the shares and noting that the company reported fiscal Q1 sales and EPS well ahead of its consensus and estimates.

In its financial results for fiscal Q1 2026, Globus Medical, Inc. (NYSE:GMED) reported worldwide net sales of $759.9 million, reflecting an increase of 27.0%, or an increase of 25.5% on a constant currency basis. Management further reported that base business, excluding Nevro, net sales were $677.2 million, up 13.2%, or an increase of 11.2% on a constant currency basis. The company headed off a strong start to the year, with record Q1 earnings and organic revenue growth driven by share gains and procedural volume strength in core spine. Keith Pfeil, President and Chief Executive Officer, also stated that Enabling Technologies delivered against its pipeline and continued to expand the company’s customer base.

Globus Medical, Inc. (NYSE:GMED) is a medical device company involved in the development and commercialization of healthcare solutions. The company classifies its products into Innovative Fusion and Disruptive Technology, and operates through the United States and International geographical segments.

While we acknowledge the risk and potential of GMED as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GMED and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1